Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Adaptive, Open-label, Single Ascending Dose to Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a), Followed by an Open-label Extension

NCT05095727 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05095727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05095727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Adaptive, Open-label, Single Ascending Dose to Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-3745 in Participants With Glycogen Storage Disease Type 1a (GSD1a), Followed by an Open-label Extension
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 1, 2022
Completion date
November 30, 2026
Enrollment
15 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

glycogen storage disease